KP-1461
KP-1461 is an experimental antiretroviral drug that was under development for the treatment of HIV/AIDS. It belongs to a class of drugs known as viral mutagens, which work by inducing high rates of mutation in the HIV virus, thereby causing it to self-destruct.
Mechanism of Action
KP-1461 works by inducing a process known as viral error catastrophe or lethal mutagenesis. This process involves the introduction of a high rate of mutations into the genetic material of the virus, which leads to the production of nonviable offspring and ultimately, the collapse of the viral population.
The drug is a nucleoside reverse transcriptase inhibitor (NRTI), which means it interferes with the action of reverse transcriptase, an enzyme that HIV uses to replicate its genetic material. However, unlike other NRTIs, KP-1461 is designed to increase, rather than decrease, the rate of mutation during this process.
Clinical Trials
KP-1461 has undergone Phase I and Phase II trials. The results of these trials suggested that the drug was well-tolerated and had a favorable safety profile. However, the drug did not show a significant reduction in viral load, which led to the discontinuation of its development.
Potential Advantages and Disadvantages
One of the potential advantages of KP-1461 is that it could overcome the problem of drug resistance, which is a major challenge in the treatment of HIV/AIDS. By causing the virus to self-destruct, the drug could potentially be effective against all strains of HIV, including those that have developed resistance to other antiretroviral drugs.
However, the approach of inducing lethal mutagenesis also carries potential risks. For example, there is a concern that the high rate of mutation could lead to the emergence of more virulent or drug-resistant strains of the virus. In addition, the long-term effects of such a high rate of mutation on the host's cells are unknown.
See Also
- Antiretroviral drug
- Viral mutagen
- HIV/AIDS
- Viral error catastrophe
- Nucleoside reverse transcriptase inhibitor
- Drug resistance
-
KP-1461
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
